Volume 25, Issue 2 (3-2021)                   IBJ 2021, 25(2): 132-139 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Rashvand Z, Kahrizi K, Najmabadi H, Najafipour R, Omrani M D. Clinical and Genetic Characteristics of Splicing Variant in CYP27A1 in an Iranian Family with Cerebrotendinous xanthomatosis. IBJ 2021; 25 (2) :132-139
URL: http://ibj.pasteur.ac.ir/article-1-3192-en.html
Clinical and Genetic Characteristics of Splicing Variant in CYP27A1 in an Iranian Family with Cerebrotendinous xanthomatosis
Zahra Rashvand , Kimia Kahrizi , Hossein Najmabadi , Reza Najafipour , Mir Davood Omrani *
Abstract:  
Background: Cerebrotendinous xanthomatosis (CTX) is a rare congenital lipid-storage disorder, leading to a progressive multisystem disease. CTX with autosomal recessive inheritance is caused by a defect in the CYP27A1 gene. Chronic diarrhea, tendon xanthomas, neurologic impairment, and bilateral cataracts are common symptoms of the disease. Methods: Three affected siblings with an initial diagnosis of non-syndromic intellectual disability were recruited for further molecular investigations. To identify the possible genetic cause(s), whole exome sequencing was performed on the proband. Sanger sequencing was applied to confirm the final variant. The clinical and molecular genetic features of the three siblings from the new CTX family and other patients with the same mutations, as previously reported, were analyzed. The CYP27A1 gene was also studied for the number of pathogenic variants and their location. Results: We found a homozygous splicing mutation, NM_000784: exon6: c.1184+1G>A, in CYP27A1 gene, which was confirmed by Sanger sequencing. Among the detected pathogenic variants, the splice site mutation had the highest prevalence, and the mutations were mostly found in exon 4. Conclusion: This study is the first to report the c.1184+1G>A mutation in Iran. Our findings highlight the other feature of the disease, which is the lack of relationship between phenotype and genotype. Due to nonspecific symptoms and delay in diagnosis, CYP27A1 genetic analysis should be the definitive method for CTX diagnosis.
Keywords: Cerebrotendinous xanthomatosis, CYP27A1, Intellectual disability, Iran, Whole exome sequencing
Full-Text [PDF 975 kb]      
Type of Study: Full Length/Original Article | Subject: Molecular Genetics & Genomics
References
1. Björkhem I, Boberg KM, Leitersdorf E. Inborn Errors in Bile Acid Biosynthesis and Storage of Sterols Other than Cholesterol. Metabolic and molecular bases of inherited disease 2001; Reterieved at: https://ommbid. mhmedical.com/content.aspx?bookId=2709§ionId=225540623.
2. Philippart M, Van BogaertL. Cholestanolosis (cerebrotendinous xanthomatosis). A follow-up study on the original family. Archives of neurology 1969; 21(6): 603-610. [DOI:10.1001/archneur.1969.00480180059004]
3. Salen G. Cholestanol deposition in cerebrotendinous xanthomatosis. A possible mechanism. Annals internal medicine 1971; 75(6): 843-851. [DOI:10.7326/0003-4819-75-6-843]
4. Duell PB, Salen G, Eichler FS, DeBarber AE, Connor SL, Casady L, Jayadev S, Kisanuki Y, Lekpreasert P, Malloy MJ, Ramdhani RA, Ziajka PE, Quinn JF, SU KG, Gller AS, Diffenderfer MR, Schaefer EJ. Diagnosis, treatment and clinical outcomes in 43 cases with cerebrotendinous xanthomatosis. Journal of clinical lipidology 2018; 12(5): 1169-1178. [DOI:10.1016/j.jacl.2018.06.008]
5. Stelten BML, Huidekoper HH, van de Warrenburg BPC, Brilstra EH, Hollak CEM, Haak HR, Kluijtmans LAJ, Wevers R, Verrips A. Long-term atreatment effect in cerebrotendinous xanthomatosis depends on ge at treatment start. Neurology 2019; 92(2): e83-e95. [DOI:10.1212/WNL.0000000000006731]
6. Degos B, Nadjar Y, del Mar Amador M, Lamari F, Sedel F, Roze E, Couvert P, Mochel F. Natural history of cerebrotendinous xanthomatosis: A paediatric disease diagnosed in adulthood. Orphanet journal of rare diseases 2016; 11: Article number 41. [DOI:10.1186/s13023-016-0419-x]
7. Salen G, Steiner RD. Epidemiology, diagnosis, and treatment of cerebrotendinous xanthomatosis (CTX). Journal of inherited metabolic disease 2017; 40(6): 771-781. [DOI:10.1007/s10545-017-0093-8]
8. Salen G, Grundy SM. The metabolism of cholestanol, cholesterol, and bile acids in cerebrotendinous xanthomatosis. Journal of clinical investigation 1973; 52(11): 2822-2835. [DOI:10.1172/JCI107478]
9. Verrips A, Hoefsloot LH, Steenbergen GC, Theelen JP, Wevers RA, Gabreëls FJ, van Engelen BG, van den Heuvel LP. Clinical and molecular genetic characteristics of patients with cerebrotendinous xanthomatosis. Brain 2000; 123(Pt5): 908-919. [DOI:10.1093/brain/123.5.908]
10. Lorincz MT, Rainier S, Thomas D, Fink JK. Cerebrotendinous xanthomatosis: possible higher prevalence than previously recognized. Archives of neurololgy 2005; 62(9): 1459‐1463. [DOI:10.1001/archneur.62.9.1459]
11. A Appadurai V, DeBarber A, Chiang PW, Patel SB, Steiner RD, Tyler C, Bonnen PE. Apparent underdiagnosis of cerebrotendinous xanthomatosis revealed by analysis of 60,000 human exomes. Molecular of genetics and metabolism 2015; 116(4): 298‐304. [DOI:10.1016/j.ymgme.2015.10.010]
12. Hu H, Kahrizi K, Musante L, Fattahi Z, Herwig R, Hosseini M, Oppitz C, Abedini SS, Suckow V, Larti F, Beheshtian M, Lipkowitz B, Akhtarkhavari T, Mehvari S, Otto S, Mohseni M, Arzhangi S, Jamali P, Mojahedi F, Taghdiri M, Papari E, Soltani Banavandi MJ, Akbari S, Tonekaboni SH, Dehghani H, Ebrahimpour MR, Bader I, Davarnia B, Cohen M, Khodaei H, Albrecht B, Azimi S, Zirn B, Bastami M, Wieczorek D, Bahrami G, Kelleman K, Nouri Vahid L, Tzschach A, Gärtner J, Gillessen-Kaesbach G, Rezazadeh Varaghchi JR, Timmermann B, Pourfatemi F, Jankhah A, Chen W, Nikuei P, Kalscheuer VM, Oladnabi M, Wienker TF, Ropers HH, Najmabadi H. Genetics of intellectual disability in consanguineous families. Molecular psychiatry 2018; 24(7): 1027-1039 [DOI:10.1038/s41380-017-0012-2]
13. Garuti R, Croce MA, Tiozzo R, Dotti MT, Federico A, Bertolini S, Calandra S. Four novel mutations of sterol 27-hydroxylase gene in Italian patients with cerebrotendinous xanthomatosis. Journal of lipid research 1997; 38(11): 2322‐2334. [DOI:10.1016/S0022-2275(20)34946-4]
14. Lee MH, Hazard S, Carpten JD, Yi S, Cohen J, Gerhardt GT, Salen G, Patel SB. Fine-mapping, mutation analyses, and structural mapping of cerebrotendinous xanthomatosis in U.S. pedigrees. Journal of lipid research 2001; 42(2): 159-169. [DOI:10.1016/S0022-2275(20)31675-8]
15. Miller SA, Dykes DD, HFRN P. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic acids research 1988; 16(3): 1215. [DOI:10.1093/nar/16.3.1215]
16. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009; 25(14): 1754-1760. [DOI:10.1093/bioinformatics/btp324]
17. McKenna A, Hanna M, Sivachenko A, Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabrial S, Daly M, DePristo MA. The genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome research 2010; 20(9): 1297-1303. [DOI:10.1101/gr.107524.110]
18. Najmabadi H, Hu H, Garshasbi M, Zemojtel T, Abedini SS, Chen W, Hosseini M, Behjati F, Haas S, Jamali P, Zecha Am Mohseni M, Puttmann L, Nouri Vahid L, Jensen C, Abbasi Moheb L, Bienek M, Larti F, Mueller I, Weissmann R, Darvish H, Wrogemann K, Hadavi V, Lipkowitz B, Esmaeeli-Nieh S, Wieczorek D, Kariminejad R, Ghasemi Firouzabadi S, Cohen M, Fattahi Z, Rost I, Mojahedi F, Hertzberg C, Dehghan A, Rajab A, Soltani Banavandi MJ, Hoffer J, Falah M, Musante L, Kalscheuer V, Ullmann R, Kuss AW, Tzschach A, Kahrizi K, Roper HH. Deep sequencing reveals 50 novel genes for recessive cognitive disorders. Nature 2011; 478: 57-63. [DOI:10.1038/nature10423]
19. Schwarz JM, Cooper DN, Schuelke M, Seelow D. MutationTaster2: mutation prediction for the deep-sequencing age. Nature methods 2014; 11(4): 361-362. [DOI:10.1038/nmeth.2890]
20. Choi Y, Chan AP. PROVEAN web server: A tool to predict the functiona leffect of amino acid substitutions and indels. Bioinformatics 2015; 311(16): 2745-2757. [DOI:10.1093/bioinformatics/btv195]
21. Pollard KS, Hubisz MJ, Rosenbloom KR, Adam S. Detection of nonneutral substitution rates on mammalian phylogenies. Genome research 2010; 20(1): 110-121. [DOI:10.1101/gr.097857.109]
22. Safran M, Dalah I, Alexander J, Rosen N, Stein TI, Shmoish M, Nativ N, Bahir I, Doniger T, Krug H, Sirota-Madi A, Olender T, Gil Stelzer Y, Harel A, Lancet HD. GeneCards Version 3: the human gene integrator. Database (Oxford) 2010; 2010: baq020. [DOI:10.1093/database/baq020]
23. Leitersdorf E, Reshef A, Meiner V, Levitzki R, Schwartz SP, Dann EJ, Berkman N, Cali JJ, Klapholz L, Berginer VM. Frameshift and splice-junction mutations in the sterol 27-hydroxylase gene cause cerebrotendinous xanthomatosis in Jews of Moroccan origin. Journal of clinical investigation 1993; 91(6): 2488-2496. [DOI:10.1172/JCI116484]
24. Andersson S, Davis DL, Dahlbäck H, Jörnvall H, Russell DW. Cloning, structure, and expression of the mitochondrial cytochrome P-450 sterol 26-hydroxylase, a bile acid biosynthetic enzyme. Journal biological chemistry 1989; 264(14): 8222-8229. [DOI:10.1016/S0021-9258(18)83172-6]
25. Wikvall K. Hydroxylations in biosynthesis of bile acids. Isolation of a cytochrome P-450 from rabbit liver mitochondria catalyzing 26-hydroxylation of C27-steroids. Journal of biological chemistry 1984; 259(6): 3800-3804. [DOI:10.1016/S0021-9258(17)43166-8]
26. Okuda KI. Liver mitochondrial P450 involved in cholesterol catabolism and vitamin D activation. 35. Journal of lipid research 1994; 35(3): 361-372. [DOI:10.1016/S0022-2275(20)41189-7]
27. Tuls J, Geren L, Millett F. Fluorescein isothiocyanate specifically modifies lysine 338 of cytochrome P-450scc and inhibits adrenodoxin binding. Journal of biological chemistry 1989; 264(28): 6421-1625. [DOI:10.1016/S0021-9258(19)84723-3]
28. Rosenberg RN, Pascual JM. Rosenberg's Molecular and Genetic Basis of Neurological and Psychiatric Disease. 5th Edition; 2015. Reterieved from: https://doi.org/ 10.1016/C2012-0-02688-9. [DOI:10.1016/C2012-0-02688-9.]
29. Clayton PT, Verrips A, Sistermans E, Mann A, Mieli-Vergani G, Wevers R. Mutations in the sterol 27-hydoxylase gene (CYP27A) cause hepatitis of infancy as well as cerebrotendinous xanthomatosis. Journal of inherited metabolic disease 2002; 25(6): 501-513. [DOI:10.1023/A:1021211520034]
30. Bhattacharyya AK, Lin DS, Connor WE. Cholestanol metabolism in patients with cerebrotendinous xanthomatosis: absorption, turnover, and tissue deposition. Journal of lipid research 2007; 48(1):185-192. [DOI:10.1194/jlr.M600113-JLR200]
31. Okuyama E, Tomita S, Takeuchi H, and Ichikawa Y. A novel mutation in the cytochrome P4502, (CYP27) gene caused cerebrotendinous xanthomatosis in a Japanese family. Journal of lipid research 1996; 37(3): 631-639. [DOI:10.1016/S0022-2275(20)37604-5]
32. Garuti R, Lelli N, Barozzini M, Tiozzo R, Dotti MT, Federico A, Ottomano AM, Croce A, Bertolini S, Calandra S. Cerebrotendinous xanthomatosis caused by two new mutations of the sterol-27-hydroxylase gene that disrupt mRNA splicing. Journal of lipid research 1996; 37(7): 1459-1467. [DOI:10.1016/S0022-2275(20)39130-6]
Add your comments about this article : Your username or Email:
CAPTCHA
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Iranian Biomedical Journal

Designed & Developed by : Yektaweb